R Adar, E W Salzman. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Administration, OralAnti-Inflammatory Agents/therapeutic useAnticoagulants/administration & dosageAnticoagulants/adverse effectsAnticoagulants/therapeutic useBlood Coagulation TestsDextrans/therapeutic useFemaleHemorrhage/chemically inducedHeparin/administration & dosageHeparin/therapeutic useHumansInjections, IntravenousLeg/blood supplyLigationPhlebitis/therapyPregnancyPregnancy Complications, Cardiovascular/drug therapyPuerperal Disorders/drug therapyPulmonary Embolism/prevention & controlStreptokinase/therapeutic useThrombophlebitis/drug therapyThrombophlebitis/surgeryThrombophlebitis/therapyTime FactorsUrokinase-Type Plasminogen Activator/therapeutic use
Substances: See more » Anti-Inflammatory AgentsAnticoagulantsDextransHeparinStreptokinaseUrokinase-Type Plasminogen Activator
Year: 1975 PMID: 1090840 DOI: 10.1056/NEJM197502132920707
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245